Wednesday, April 4, 2012

UCB and Amgen Initiate Sclerostin Antibody Phase 3 Program in Patients With Postmenopausal Osteoporosis

First Patient Randomized Marks Start of Phase 3 Program to Evaluate Safety and Efficacy of CDP7851/AMG 785 in Women With Postmenopausal Osteoporosis BRUSSELS and THOUSAND OAKS, Calif., April 4, 2012 /PRNewswire/ -- UCB (Euronext Brussels: UCB) and Amgen (NASDAQ:AMGN) announced today the start of their sclerostin antibody (CDP7851/AMG 785) Phase 3 clinical trial program for the treatment of postmenopausal osteoporosis. "We look forward to working with UCB on the CDP7851/AMG 785 Phase 3 program...continued
      

URL: http://www.investorpoint.com/news/INTHPINK/50021986/

Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)